CTOs on the Move

BioInnovation Capital

www.bioinnovation.co

 
BioInnovation Capital invests in the most promising life science companies in residence at premier co-working laboratory facilities where our partners are on-site every day. As the first investment platform to knit together a national network of co-working laboratories, we have a unique lens and an unparalleled position from which to invest. Our partners are located in: Cambridge, MA (BioLabs and LabCentral); Durham, North Carolina (BioLabs North Carolina); San Francisco, and San Diego, CA (BioLabs San Diego).​ Our perspective is characterized by superb access to key innovators in academia, as well as to the corporate partners who are likely ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioInnovation Capital raised $65.6M on 02/16/2017

Similar Companies

Phio Pharmaceuticals

Developing the next generation of immuno-oncology therapeutics

Cell Signaling Technology

Cell Signaling Technology, Inc. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision NanoSystem

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.

MAIA Biotechnology

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs

Myriad

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.